As we have seen, anticholinergic risk studies have been inconsistent as to whether quetiapine present a low-, moderate- or high-risk, in spite of having been linked to greater cognitive decline in Alzheimer’s disease by Ballard et al. (2005) The pharmacokinetic variability of quetiapine in patients has been established and also correlated with age and CYP3A4 inducers (Bakken et al., 2011), as well as tentatively linked to therapeutic effects (Rovera et al., 2017). The gene discussed is CYP3A4; the disease is early-onset autosomal dominant Alzheimer disease.